Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults

Alzheimer’s Disease Neuroimaging Initiative (ADNI), Sungeun Kim

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Depressive symptoms are common in older adults and are particularly prevalent in those with or at elevated risk for dementia. Although the heritability of depression is estimated to be substantial, single nucleotide polymorphism-based genome-wide association studies of depressive symptoms have had limited success. In this study, we performed genome-wide gene- and pathway-based analyses of depressive symptom burden. Study participants included non-Hispanic Caucasian subjects (n = 6,884) from three independent cohorts, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Health and Retirement Study (HRS), and the Indiana Memory and Aging Study (IMAS). Gene-based meta-analysis identified genome-wide significant associations (ANGPT4 and FAM110A, q-value = 0.026; GRM7-AS3 and LRFN5, q-value = 0.042). Pathway analysis revealed enrichment of association in 105 pathways, including multiple pathways related to ERK/MAPK signaling, GSK3 signaling in bipolar disorder, cell development, and immune activation and inflammation. GRM7, ANGPT4, and LRFN5 have been previously implicated in psychiatric disorders, including the GRM7 region displaying association with major depressive disorder. The ERK/MAPK signaling pathway is a known target of antidepressant drugs and has important roles in neuronal plasticity, and GSK3 signaling has been previously implicated in Alzheimer’s disease and as a promising therapeutic target for depression. Our results warrant further investigation in independent and larger cohorts and add to the growing understanding of the genetics and pathobiology of depressive symptoms in aging and neurodegenerative disorders. In particular, the genes and pathways demonstrating association with depressive symptoms may be potential therapeutic targets for these symptoms in older adults.

Original languageEnglish (US)
Title of host publicationHandbook of Depression in Alzheimer's Disease
PublisherIOS Press
Pages313-322
Number of pages10
ISBN (Print)9781614995425, 9781614995418
DOIs
StatePublished - Jan 1 2015

Fingerprint

Depression
Genes
Alzheimer Disease
Genome
Neuronal Plasticity
Retirement
Genome-Wide Association Study
Major Depressive Disorder
Bipolar Disorder
Neuroimaging
Neurodegenerative Diseases
Antidepressive Agents
Single Nucleotide Polymorphism
Psychiatry
Dementia
Meta-Analysis
Inflammation
Health
Therapeutics

Keywords

  • ANGPT4
  • Depressive symptoms
  • Genome-wide association study
  • GRM7
  • GSK3
  • MAPK-ERK

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Alzheimer’s Disease Neuroimaging Initiative (ADNI), & Kim, S. (2015). Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. In Handbook of Depression in Alzheimer's Disease (pp. 313-322). IOS Press. https://doi.org/10.3233/978-1-61499-542-5-313

Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. / Alzheimer’s Disease Neuroimaging Initiative (ADNI); Kim, Sungeun.

Handbook of Depression in Alzheimer's Disease. IOS Press, 2015. p. 313-322.

Research output: Chapter in Book/Report/Conference proceedingChapter

Alzheimer’s Disease Neuroimaging Initiative (ADNI) & Kim, S 2015, Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. in Handbook of Depression in Alzheimer's Disease. IOS Press, pp. 313-322. https://doi.org/10.3233/978-1-61499-542-5-313
Alzheimer’s Disease Neuroimaging Initiative (ADNI), Kim S. Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. In Handbook of Depression in Alzheimer's Disease. IOS Press. 2015. p. 313-322 https://doi.org/10.3233/978-1-61499-542-5-313
Alzheimer’s Disease Neuroimaging Initiative (ADNI) ; Kim, Sungeun. / Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. Handbook of Depression in Alzheimer's Disease. IOS Press, 2015. pp. 313-322
@inbook{190c6d6ce74e45d8bfa6091c41389dee,
title = "Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults",
abstract = "Depressive symptoms are common in older adults and are particularly prevalent in those with or at elevated risk for dementia. Although the heritability of depression is estimated to be substantial, single nucleotide polymorphism-based genome-wide association studies of depressive symptoms have had limited success. In this study, we performed genome-wide gene- and pathway-based analyses of depressive symptom burden. Study participants included non-Hispanic Caucasian subjects (n = 6,884) from three independent cohorts, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Health and Retirement Study (HRS), and the Indiana Memory and Aging Study (IMAS). Gene-based meta-analysis identified genome-wide significant associations (ANGPT4 and FAM110A, q-value = 0.026; GRM7-AS3 and LRFN5, q-value = 0.042). Pathway analysis revealed enrichment of association in 105 pathways, including multiple pathways related to ERK/MAPK signaling, GSK3 signaling in bipolar disorder, cell development, and immune activation and inflammation. GRM7, ANGPT4, and LRFN5 have been previously implicated in psychiatric disorders, including the GRM7 region displaying association with major depressive disorder. The ERK/MAPK signaling pathway is a known target of antidepressant drugs and has important roles in neuronal plasticity, and GSK3 signaling has been previously implicated in Alzheimer’s disease and as a promising therapeutic target for depression. Our results warrant further investigation in independent and larger cohorts and add to the growing understanding of the genetics and pathobiology of depressive symptoms in aging and neurodegenerative disorders. In particular, the genes and pathways demonstrating association with depressive symptoms may be potential therapeutic targets for these symptoms in older adults.",
keywords = "ANGPT4, Depressive symptoms, Genome-wide association study, GRM7, GSK3, MAPK-ERK",
author = "{Alzheimer’s Disease Neuroimaging Initiative (ADNI)} and Kwangsik Nho and Ramanan, {Vijay K.} and Sungeun Kim and Sungeun Kim and Inlow, {Mark H.} and Risacher, {Shannon L.} and Brenna McDonald and Martin Farlow and Tatiana Foroud and Sujuan Gao and Christopher Callahan and Hugh Hendrie and Alexander Niculescu and Andrew Saykin",
year = "2015",
month = "1",
day = "1",
doi = "10.3233/978-1-61499-542-5-313",
language = "English (US)",
isbn = "9781614995425",
pages = "313--322",
booktitle = "Handbook of Depression in Alzheimer's Disease",
publisher = "IOS Press",

}

TY - CHAP

T1 - Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults

AU - Alzheimer’s Disease Neuroimaging Initiative (ADNI)

AU - Nho, Kwangsik

AU - Ramanan, Vijay K.

AU - Kim, Sungeun

AU - Kim, Sungeun

AU - Inlow, Mark H.

AU - Risacher, Shannon L.

AU - McDonald, Brenna

AU - Farlow, Martin

AU - Foroud, Tatiana

AU - Gao, Sujuan

AU - Callahan, Christopher

AU - Hendrie, Hugh

AU - Niculescu, Alexander

AU - Saykin, Andrew

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Depressive symptoms are common in older adults and are particularly prevalent in those with or at elevated risk for dementia. Although the heritability of depression is estimated to be substantial, single nucleotide polymorphism-based genome-wide association studies of depressive symptoms have had limited success. In this study, we performed genome-wide gene- and pathway-based analyses of depressive symptom burden. Study participants included non-Hispanic Caucasian subjects (n = 6,884) from three independent cohorts, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Health and Retirement Study (HRS), and the Indiana Memory and Aging Study (IMAS). Gene-based meta-analysis identified genome-wide significant associations (ANGPT4 and FAM110A, q-value = 0.026; GRM7-AS3 and LRFN5, q-value = 0.042). Pathway analysis revealed enrichment of association in 105 pathways, including multiple pathways related to ERK/MAPK signaling, GSK3 signaling in bipolar disorder, cell development, and immune activation and inflammation. GRM7, ANGPT4, and LRFN5 have been previously implicated in psychiatric disorders, including the GRM7 region displaying association with major depressive disorder. The ERK/MAPK signaling pathway is a known target of antidepressant drugs and has important roles in neuronal plasticity, and GSK3 signaling has been previously implicated in Alzheimer’s disease and as a promising therapeutic target for depression. Our results warrant further investigation in independent and larger cohorts and add to the growing understanding of the genetics and pathobiology of depressive symptoms in aging and neurodegenerative disorders. In particular, the genes and pathways demonstrating association with depressive symptoms may be potential therapeutic targets for these symptoms in older adults.

AB - Depressive symptoms are common in older adults and are particularly prevalent in those with or at elevated risk for dementia. Although the heritability of depression is estimated to be substantial, single nucleotide polymorphism-based genome-wide association studies of depressive symptoms have had limited success. In this study, we performed genome-wide gene- and pathway-based analyses of depressive symptom burden. Study participants included non-Hispanic Caucasian subjects (n = 6,884) from three independent cohorts, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Health and Retirement Study (HRS), and the Indiana Memory and Aging Study (IMAS). Gene-based meta-analysis identified genome-wide significant associations (ANGPT4 and FAM110A, q-value = 0.026; GRM7-AS3 and LRFN5, q-value = 0.042). Pathway analysis revealed enrichment of association in 105 pathways, including multiple pathways related to ERK/MAPK signaling, GSK3 signaling in bipolar disorder, cell development, and immune activation and inflammation. GRM7, ANGPT4, and LRFN5 have been previously implicated in psychiatric disorders, including the GRM7 region displaying association with major depressive disorder. The ERK/MAPK signaling pathway is a known target of antidepressant drugs and has important roles in neuronal plasticity, and GSK3 signaling has been previously implicated in Alzheimer’s disease and as a promising therapeutic target for depression. Our results warrant further investigation in independent and larger cohorts and add to the growing understanding of the genetics and pathobiology of depressive symptoms in aging and neurodegenerative disorders. In particular, the genes and pathways demonstrating association with depressive symptoms may be potential therapeutic targets for these symptoms in older adults.

KW - ANGPT4

KW - Depressive symptoms

KW - Genome-wide association study

KW - GRM7

KW - GSK3

KW - MAPK-ERK

UR - http://www.scopus.com/inward/record.url?scp=84947808224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947808224&partnerID=8YFLogxK

U2 - 10.3233/978-1-61499-542-5-313

DO - 10.3233/978-1-61499-542-5-313

M3 - Chapter

SN - 9781614995425

SN - 9781614995418

SP - 313

EP - 322

BT - Handbook of Depression in Alzheimer's Disease

PB - IOS Press

ER -